Prescient Therapeutics Limited (ASX:PTX)

Market Cap	68.35M +62.5%
Revenue (ttm)	3.45M -20.8%
Net Income	-7.00M
EPS	-0.01
Shares Out	1.05B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	948,963
Open	0.0660
Previous Close	0.0650
Day's Range	0.0660 - 0.0690
52-Week Range	0.0400 - 0.1250
Beta	0.75
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 24, 2026

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PTX

Financial Performance

In fiscal year 2026, Prescient Therapeutics's revenue was 3.45 million, a decrease of -20.78% compared to the previous year's 4.36 million. Losses were -7.00 million, -4.37% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error